GeneDx Corp (WGS) - Market Value to Book Value Ratio

Corporate company logo of GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. (WGS) is reaching operational profitability by focusing on pediatric genomic sequencing, while demand for its services remains economy-independent and stands at 8.71. The company maintains pricing power due to its unique exome archive. This daily price chart for GeneDx Holdings Corp. (WGS) illustrates the quotes for the genetic testing developer. However, the risk of dumping by network laboratories and fierce competition for hospital contracts pose serious threats.

GeneDx Corp (WGS) - Market Capitalization to Book Value Ratio from 04/28/2023 to 10/30/2026

Analytical breakdowns for GeneDx Holdings Corp.

- share price and expert price forecast:
Stock Price GeneDx Holdings Corp.|WGS - Broker Consensus Forecast
- market capitalization indicators:
Market Value Sema4|WGS - Business Value
- book capitalization data:
Book Value per Share GeneDx|WGS - Book Capitalization|Market Capitalization to Book Value Ratio genedx.com|WGS - Company Balance Sheet Assets
- debt and solvency information:
Total Debt to Capital GeneDx Holdings Corp.|WGS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Sema4|WGS - Company Aggregate Debt|Debts to Book Capitalization Sema4|WGS - Long-Term Debt|Company Short-Term Debts GeneDx|Quick Liquidity Indicator genedx.com
- earnings and valuation multiples indicators:
WGS - Company Profit
Summary company analysis:GeneDx Holdings Corp. - WGS
Flagship merchandise of Sema4

This multiple determines the investment reliability of GeneDx Holdings Corp. (WGS) by comparing the business's market value with its net assets to identify whether capital is overvalued or undervalued. By analyzing the current market value to book value ratio on the GURU.Markets platform, an investor can discern market expectations regarding the scaling of whole-genome sequencing and the monetization of unique genetic data in rare disease diagnostics.

Analysis of competing companies

TEM: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio QGEN|Market Value to Book Value Ratio Ionis|Capitalization to Book Value Ratio RGEN (Repligen Corp)|Market Capitalization to Book Value Ratio RNA|Market Capitalization to Book Value Ratio CRISPR (CRSP)|Market Capitalization to Book Value Ratio RARE (Ultragenyx Pharmaceutical)|Market Value to Equity Ratio beamtx.com|Sarepta - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Twist Bioscience Inc|10x Genomics Corp (TXG) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio NTLA|STOK (Stoke Therapeutics) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio biolifesolutions.com BLFS|Market Capitalization to Book Value Ratio WVE|Maze Therapeutics, Inc. - Capitalization to Book Value Ratio|Sionna Pharma - Market Cap to Net Assets Ratio|PRME: Capitalization to Book Value Ratio|TSHA: Market Cap to Net Assets Ratio|Market Value to Book Value QURE (uniqure.com)|MGTX: Market Capitalization to Book Value Ratio|REGENXBIO Inc - Market Value to Book Value|Market Value to Book Value Ratio Solid Bio|Market-to-Book Ratio Ocugen Pharma OCGN|Market Value to Book Value Ratio Pacific Biosciences (PACB)|Market Value to Book Value Ratio BNTC (benitec.com)|Market Capitalization to Book Value Ratio DSGN (Design Therapeutics, Inc.)|RCKT: Capitalization to Book Value Ratio|4D Molecular Therapeutics Inc - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Lexeo Therapeutics LXEO|korrobio.com (KRRO) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio EDIT|SLN (Silence Therapeutics plc) - Market Capitalization to Book Value Ratio|PRQR - Market Value to Equity Ratio|Market Value to Book Value Ratio Codexis, Inc. (CDXS)|Market Capitalization to Book Value Sangamo BioSciences|Nautilus Bio - Market Cap to Net Assets Ratio|Market Value to Book Value MGX|Precision BioSciences - Market Capitalization to Book Value Ratio|Generation Bio Co. (GBIO) - Market Cap to Net Assets Ratio|Boundless Bio, Inc (BOLD) - Market Value to Book Value Ratio|Market-to-Book Ratio Exicure (XCUR)|Market Value to Book Value Ratio Imunon Inc|PHIO: Market Value to Book Value|Market Value to Book Value Ratio Mustang Bio, Inc. (MBIO)|RNAZ: Market Capitalization to Net Assets|Bionano Genomics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Applied DNA Corp (APDN)|BLUE: Market Cap to Net Assets Ratio|ImmunoPrecise Antibodies (IPA) - Market Cap to Net Assets Ratio|OMGA: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Singular Genomics Systems, Inc. OMIC|Market Value to Book Value Ratio Regulus Therapeutics Inc|Syros Pharmaceuticals, Inc (SYRS) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio TBIO|traconpharma.com - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Unity Biotechnology, Inc. UBX